Inhalable metal-organic framework-mediated cuproptosis combined with PD-L1 checkpoint blockade for lung metastasis synergistic immunotherapy

• Published in: Acta pharmaceutica Sinica. B Vol. 14; no. 5; pp. 2281 - 2297
• Main Authors: Yan, Chongzheng, Liu, Ying, Zhao, Guozhi, Yang, Huatian, Lv, Huaiyou, Li, Genju, Li, Yuhan, Fu, Yaqing, Sun, Fengqin, Feng, Yafei, Li, Yizhe, Zhao, Zhongxi
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier 01.05.2024
• Subjects: Copper-based metal-organic framework; Cuproptosis; Immunogenic cell death; Immunotherapy; PD-L1 checkpoint blockade; Tumor microenvironment; PD-L1 checkpoint blockade; Lung metastasis; Tumor microenvironment; Cuproptosis; Immunotherapy; Transmucosal delivery; Copper-based metal-organic framework; Immunogenic cell death
• ISSN: 2211-3835
• DOI: 10.1016/j.apsb.2024.01.017

Cuproptosis shows enormous application prospects in lung metastasis treatment. However, the glycolysis, Cu efflux mechanisms, and insufficient lung drug accumulation severely restrict cuproptosis efficacy. Herein, an inhalable poly (2-( -oxide- , -diethylamino)ethyl methacrylate) (OPDEA)-coated copper-based metal-organic framework encapsulating pyruvate dehydrogenase kinase 1 siRNA (siPDK) is constructed for mediating cuproptosis and subsequently promoting lung metastasis immunotherapy, namely OMP. After inhalation, OMP shows highly efficient lung accumulation and long-term retention, ascribing to the OPDEA-mediated pulmonary mucosa penetration. Within tumor cells, OMP is degraded to release Cu under acidic condition, which will be reduced to toxic Cu to induce cuproptosis under glutathione (GSH) regulation. Meanwhile, siPDK released from OMP inhibits intracellular glycolysis and adenosine-5'-triphosphate (ATP) production, then blocking the Cu efflux protein ATP7B, thereby rendering tumor cells more sensitive to OMP-mediated cuproptosis. Moreover, OMP-mediated cuproptosis triggers immunogenic cell death (ICD) to promote dendritic cells (DCs) maturation and CD8 T cells infiltration. Notably, OMP-induced cuproptosis up-regulates membrane-associated programmed cell death-ligand 1 (PD-L1) expression and induces soluble PD-L1 secretion, and thus synergizes with anti-PD-L1 antibodies (aPD-L1) to reprogram immunosuppressive tumor microenvironment, finally yielding improved immunotherapy efficacy. Overall, OMP may serve as an efficient inhalable nanoplatform and afford preferable efficacy against lung metastasis through inducing cuproptosis and combining with aPD-L1.